Phase 1 DLBCL Clinical Trials
12 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–12 of 12 trials
Recruiting
Phase 1Phase 2
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Non-Hodgkin LymphomaMantle Cell LymphomaFollicular Lymphoma+6 more
BeiGene146 enrolled29 locationsNCT05294731
Recruiting
Phase 1Phase 2
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
DLBCL - Diffuse Large B Cell LymphomaLymphomaLymphoplasmacytic Lymphoma+4 more
ModeX Therapeutics, An OPKO Health Company180 enrolled1 locationNCT07249905
Recruiting
Phase 1
P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
High-grade B-cell LymphomaDLBCL - Diffuse Large B Cell LymphomaPrimary Mediastinal Large B-cell Lymphoma (PMBCL)+7 more
Poseida Therapeutics, Inc.120 enrolled17 locationsNCT06014762
Recruiting
Phase 1
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
DLBCL - Diffuse Large B Cell LymphomaFollicular Lymphoma ( FL)Mantle Cell Lymphoma (MCL)+2 more
LTZ Therapeutics, Inc.42 enrolled5 locationsNCT07121946
Recruiting
Phase 1
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
Lymphoma, B-CellChronic Lymphocytic Leukemia (CLL)Lymphoma, Non-Hodgkin (NHL)+1 more
Umoja Biopharma106 enrolled8 locationsNCT06528301
Recruiting
Phase 1
Optimizing lymphoDepletion to Improve Outcomes In Patients Receiving Cell Therapy With Yescarta
DLBCL - Diffuse Large B Cell Lymphoma
University Health Network, Toronto40 enrolled1 locationNCT05950802
Recruiting
Phase 1
A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies
NeoplasmsMultiple Myeloma in RelapseMultiple Myeloma, Refractory+2 more
Technische Universität Dresden16 enrolled1 locationNCT05836896
Recruiting
Phase 1Phase 2
A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)
Advanced Solid TumorDLBCL
Ranok Therapeutics (Hangzhou) Co., Ltd.32 enrolled5 locationsNCT05487170
Completed
Phase 1
Part C: A Study of SGR-1505 in Healthy Volunteer Participants
Activated B-cell diff use large B-cell lymphoma (ABC-DLBCL)
Schrödinger, Inc.12 enrolled1 locationACTRN12623000464662
Completed
Phase 1
Part A, B and D: A Study of SGR-1505 in Healthy Volunteer Participants
Activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL)
Schrödinger, Inc66 enrolled1 locationACTRN12623000358640
Recruiting
Phase 1Phase 2
Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse
DLBCL
Stichting Hemato-Oncologie voor Volwassenen Nederland37 enrolled1 locationNCT03356054
Recruiting
Phase 1Phase 2
Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement
DLBCLUntreatedMYC Gene Rearrangement
The First Affiliated Hospital with Nanjing Medical University81 enrolled1 locationNCT04432714